
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Chesapeake IRB-technology-enabled independent institutional review board (IRB) that serves the clinical research industry-has acquired MaGil IRB.
The acquisition provides Chesapeake with additional AAHRPP-accredited review capacity and more staff, broadening its precense for CROs, pharma companes, and biotech companies.
Read the full release






